OpenBiome, a nonprofit supplying fecal microbiota transplantation (FMT) material, announced a voluntary suspension of its distribution this week, affecting many clinical sites across the U.S. Although the FDA’s current enforcement policy permits FMT use for C. difficile infections unresponsive to standard treatments, the future of this policy is uncertain. The American Gastroenterological Association (AGA) is actively advocating to maintain access to conventional FMT for patients with severe C. diff infections who may not be eligible for recently FDA-approved microbial therapies. In collaboration with infectious disease experts and related organizations, AGA submitted a letter to the FDA, stressing the need for…
Author: Abhay Panchal
The recent multisociety clinical practice document provides guidance on the perioperative management of GLP-1 receptor agonists (GLP-1RAs), emphasizing shared decision-making and tailored patient care. Here are key points from the recommendations:
A new study presented at the American College of Gastroenterology 2024 meeting suggests that a wireless motility patch system could offer a more comprehensive, noninvasive way to monitor multiday gastrointestinal (GI) activity. Led by Dr. Brian Lacy and colleagues from the Mayo Clinic, the study used wireless patches on 37 patients to record colonic myoelectrical activity continuously over several days. Findings indicated that higher nighttime GI activity correlated with improved bowel movement satisfaction among patients. This technology challenges traditional methods, which typically capture brief “snapshots” using gastric emptying scintigraphy or high-resolution manometry—both limited in scope, invasive, and generally confined to…
Guardant Health’s Shield™, a pioneering blood test for colorectal cancer screening, has been included in TIME magazine’s 2024 list of the Best Inventions, which recognizes 200 innovations impacting healthcare, AI, and other fields. Shield, which gained FDA approval and Medicare reimbursement earlier in 2024, is celebrated for its ability to detect colorectal cancer at earlier stages, potentially saving lives by offering a less invasive, accessible screening option. The selection highlights Guardant’s commitment to transforming cancer diagnostics, as the company reaches milestones of 500 peer-reviewed publications and over 500,000 patient tests. Guardant co-CEO AmirAli Talasaz noted the honor as a testament…
A recent study by WovenX Health showcased the potential of on-demand telehealth in cutting emergency department (ED) visits and associated healthcare costs for gastrointestinal (GI) symptoms. With GI issues being one of the top reasons for non-admission ED visits, the study estimates that unnecessary ED visits lead to over $30 billion in avoidable spending yearly. Key findings revealed that out of 501 patients using WovenX’s on-demand GI telehealth platform, over 40% would have otherwise sought care in the ED or urgent care.
A recent study published in Clinical Gastroenterology and Hepatology suggests that individuals with no detectable fecal hemoglobin (f-Hb) in prior negative fecal immunochemical tests (FITs) have a significantly higher harm-to-benefit ratio for colorectal cancer (CRC) screening. Led by Esther Toes-Zoutendijk, PhD, the research found that the number needed to screen (NNS) to detect advanced adenomas or CRC was notably higher among individuals with undetectable f-Hb, implying reduced screening effectiveness.
A new book from the American Association for Physician Leadership (AAPL), Private Equity and Healthcare: Leadership, Economics, and Trends for the Future, authored by Max Reiboldt, CPA, delves into the growing influence of private equity (PE) in U.S. healthcare. The book provides a balanced analysis of PE’s impact, equipping healthcare leaders to make informed decisions. It highlights the potential for innovation and efficiency alongside challenges to patient care quality. Contributions from industry experts offer insights into managing these complexities. The book aims to guide physicians and healthcare leaders as they navigate the evolving landscape of PE investments.
Physicians Practice has released its 2024 ranking of the best U.S. states for practicing medicine, using seven key criteria: cost of living, physician density, state business tax levels, malpractice insurance rates, quality of life, women’s healthcare, and Geographic Practice Cost Indices (GPCI). These rankings provide insights into which states offer the most favorable conditions for physicians, drawing from publicly available data and insights from Physicians Practice partners.
Blue Cross Blue Shield has agreed to a $2.8 billion settlement to resolve antitrust claims from hospitals and healthcare providers, marking the largest healthcare antitrust settlement to date. The lawsuit, filed in 2012, accused Blue Cross of dividing territories to limit competition, inflating insurance costs, and underpaying providers. In addition to the monetary settlement, Blue Cross will implement operational changes, including a new information platform for claims transparency and increased contracting opportunities for providers. The deal, subject to court approval, follows a similar $2.7 billion settlement with subscribers in 2020, which the U.S. Supreme Court upheld earlier this year.
In the latest episode of The Scope with Dr. K, Dr. Lawrence Kosinski interviews Leo Grady, CEO of Jona, about how AI is transforming microbiome research and healthcare. Jona’s AI-driven insights connect gut health to areas like brain function, metabolism, and physical performance, offering personalized recommendations for diet, lifestyle, and medications. The discussion highlights Jona’s future plans for diagnostics and therapeutics, emphasizing the potential for routine microbiome testing to prevent illness and enhance holistic care.